000			03052naaaa2200409uu 4500
001			https://directory.doabooks.org/handle/20.500.12854/58619
005			20220219214233.0
020			_a9783038971177
020			_a9783038971184
041	0		_aEnglish
042			_adc
100	1		_aVéronique Baud (Ed.) _4auth
245	1	0	_aRoles of NF-κB in Cancer and Their Therapeutic Approaches
260			_bMDPI - Multidisciplinary Digital Publishing Institute _c2018
300			_a1 electronic resource (X, 330 p.)
506	0		_aOpen Access _2star _fUnrestricted online access
520			_aAlthough mortality rates have declined in recent years, the majority of cancers are still difficult to treat and the medical need for better cancer treatment is evident. The current anticancer armamentarium includes many active agents that are applied across tumor types. However, most of these broadly-active anticancer drugs have a small therapeutic index and barely discriminate between malignant and normal cells. In recent years the focus has shifted to the development of rationally designed, molecularly-targeted therapy for the treatment of a specific cancer, therefore offering the promise of greater specificity coupled with reduced systemic toxicity. NF-kB transcription factor family as emerged as such a promising target for cancer therapy. This Special Issue will explore the routes from NF-kB basic research, cancer research and oncogenomics into the development of NF-kB-based cancer therapeutics and biomarkers. We invite research and review papers in any area of the NF-kB field that are related, but not limited to, fundamental understanding of NF-kB signaling pathways, gene expression profiling, epigenetic regulation, diagnostic, prognostic and pharmacogenomic biomarkers, molecular targets driving the progression of human cancers, cancer drug development on these targets, clinical trial with new agents, and validation in animal models. We hope that this Special Issue reflects the exciting era that we are living in with respect to the field of NF-kB and its applications in cancer research.
540			_aCreative Commons _fhttps://creativecommons.org/licenses/by-nc-nd/4.0/ _2cc _4https://creativecommons.org/licenses/by-nc-nd/4.0/
546			_aEnglish
653			_asolid tumors hematological malignancies
653			_aanimal models
653			_abiomarkers
653			_acancer targeted therapeutics
653			_aoncogenomics
653			_amechanism-based drug development
653			_acancer targeted diagnosis
653			_amolecular targets
653			_aNF-kB subunit
653			_aepigenetics
653			_aNF-kB signaling pathways
653			_amiRNA
653			_aubiquitin-proteasome pathway
653			_aclinical trials
653			_agene expression profiling
856	4	0	_awww.oapen.org _uhttp://www.mdpi.com/books/pdfview/book/711 _70 _zDOAB: download the publication
856	4	0	_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/58619 _70 _zDOAB: description of the publication
999			_c45641 _d45641